13 a 17 de fevereiro de 2006
CURRICULUM VITAE DOS PROFESSORES
Biographical Summary for Simon F. Campbell, PhD,
Simon Campbell is a synthetic organic chemist who received his BSc. (1962)
and PhD (1965) degrees from Birmingham University in the UK. He then carried
out postdoctoral research in Birmingham, Chile and at Stanford University
with W.S.Johnson, before being appointed Visiting Professor at the Universidade
de Sao Paulo, Brasil in 1970.
In 1972, Dr. Campbell joined Pfizer Central Research, Sandwich, as a medicinal
chemist, and he retired from Pfizer in October 1998 as Senior Vice President
for World-wide Discovery and Medicinal R&D Europe. He has co-authored over
110 publications and patents, and was a key member of the research teams
that discovered doxazosin (CarduraTM) and amlodipine (NorvascTM). Both of
these novel medicines became the leading agents worldwide in their therapeutic
class. In addition, he was senior author on the research proposal that led
to sildenafil (ViagraTM), the first oral treatment for Male Erectile Dysfunction.
Dr. Campbell's scientific contributions have been recognised by the Royal
Society of Chemistry Award for Medicinal Chemistry (1989), the Herschberg
Award from the American Chemical Society (1997), and the Industry Research
Institute (US) Achievement Award (1997). He was elected Fellow of the Royal
Society (1999) and Fellow of the Academy of Medical Sciences (2002) and
was admitted to the degree of Doctor of Science honoris causa by the University
of Kent at Canterbury (1999) and the University of Birmingham (2004). Dr.
Campbell has served on various professional and research bodies including
SERC Organic Chemistry Sub-Committee, Science Board, LINK Asymmetric Synthesis,
ABPI R&D Committee, Chemistry RAE Panel (2001) and as Visiting Professor
at the University of Leeds and Birkbeck College. He also served as Chair
of the Expert Scientific Advisory Committee for the Medicines for Malaria
Venture (Geneva, 1999-2003) and as a member of the British Petroleum Technology
Advisory Council (2000-04). Dr Campbell is a Fellow of the Royal Society
of Chemistry, and a member of the American Chemical Society.
Currently, Dr. Campbell is a member of the SABs of Astex (Cambridge), Chroma
(Oxford), DanioLabs (Cambridge) Inpharmatica (London), Merlion (Singapore)
S*Bio (Singapore), Sunesis (San Francisco), and the Conway Institute (Dublin).
He acts as consultant to Abingworth Management (London) Almirall (Barcelona)
and Jerini (Berlin). He is President of the Royal Society of Chemistry,
serves on the Council of the University of Kent and the Advisory Council
for Save British Science.